Inhibition of ex vivo-expanded cytotoxic T-lymphocyte function by high-dose cyclosporine

Transplantation

Volumn 76, Issue 4, 2003, Pages 739-741

  Zhan, Xiaoyan ^a   Brown, Brita ^a   Slobod, Karen S ^a,b   Hurwitz, Julia L ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMIUM; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2;

ALLOIMMUNITY; ARTICLE; B LYMPHOBLAST; COCULTURE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG MEGADOSE; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; LYMPHOCYTE CULTURE; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

CYCLOSPORINE; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOSUPPRESSIVE AGENTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0041835914     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000078623.64968.E5     Document Type: Article

References (11)

1. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2: 551.
2. Riddell SR, Reusser P, Greenberg PD. Cytotoxic T cells specific for cytomegalovirus: a potential therapy for immunocompromised patients. Rev Infect Dis 1991; 13(suppl 11): S966.
3. Sigal NH, Dumont FJ. Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 1992; 10: 519.
4. Rogers AM, Thilenius ARB, Russell JH. Cyclosporine-insensitive partial signaling and multiple roles of Ca2+ in Fas ligand-induced lysis. J Immunol 1997; 159: 3140.
5. D'Costa S, Slobod KS, Benaim E, et al. Effect of extended immunosuppressive drug treatment on B cell vs. T cell reconstitution in pediatric bone marrow transplant recipients. Bone Marrow Transpl 2001; 28: 573.
6. Parquet N, Reigneau O, Humbert H, et al. New oral formulation of cyclo sporin A (Neoral) pharmacokinetics in allogeneic bone marrow transplant recipients. Bone Marrow Transpl 2000; 25: 965.
7. Schultz KR, Nevill TJ, Balshaw RF, et al. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation. Bone Marrow Transpl 2000; 26: 545.
8. Contassot E, Robinet E, Angonin R, et al. Differential effects of cyclosporin A on the alloreactivity of fresh and ex vivo-expanded T lymphocytes. Bone Marrow Transpl 1998; 22: 1097.
9. Savoldo B, Goss J, Liu Z, et al. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation 2001; 72: 1078.
10. Gottschalk S, Ng CY, Perez M, et al. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 2001; 97: 835.
11. Starzl TE, Porter KA, Iwatsuki S, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583.